1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH, CDC, and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44]) is sponsored by National Cancer Institute (NCI). This omnibus solicitation supports small business innovation research across a broad spectrum of topic areas relevant to the NCI's mission, including therapeutics, diagnostics, imaging technologies, devices for cancer therapy, tools for cancer biology research, technologies for …
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NCI SBIR/STTR Omnibus Grant Solicitations - NCI NCI SBIR/STTR Omnibus Grant Solicitations The Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Omnibus Solicitations are intended to support small business innovation research across a broad spectrum of topic areas.
U.S. small businesses that have the research capabilities and technological expertise to contribute to the research and development missions of the awarding components identified in the Omnibus Solicitation are encouraged to submit investigator-initiated SBIR & STTR grant applications in response to the identified topics.
Applicants may also consider other areas of research within the mission of any of the awarding components and submit an SBIR & STTR application Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms continue to be eligible to apply to the CDC and NIH SBIR program and compete for up to 15% and 25% respectively of each agency's SBIR set-aside.
Omnibus Solicitation Opportunities This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.
SBIR Program: PA-27-100 (Clinical Trial Optional) NIH, CDC, and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2026; January 5, 2027; April 5, 2027 STTR Program: PA-27-102 (Clinical Trial Optional) NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2026; January 5, 2027; April 5, 2027 Online HTML Application Guide SF424 (R&R) Application Guide for SBIR/STTR Grant Applications (Version i) Annotated SF424 SBIR/STTR Form Set NIH Matchmaker - Use NIH Matchmaker to conduct keyword searches on a particular topic area to identify NIH Institutes or Centers (ICs) that have previously funded research area.
According to the current listing, eligibility includes: U. S. small business concerns with research capabilities and technological expertise relevant to NIH's mission, including those majority-owned by venture capital operating companies, hedge funds, or private equity firms. Confirm the full requirements in the official notice before applying.
NIH, CDC, and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44]) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article